ReviewAnnals of clinical and translational neurology2021
The influence of white matter hyperintensity on cognitive impairment in Parkinson's disease.
Review in Annals of clinical and translational neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Comparative analysis of white matter signal alterations in dementia with Lewy bodies and Alzheimer's disease: a systematic review and meta-analysis.Frontiers in radiology · 2025Pooled it
- Acupuncture for Mild Cognitive Impairment in Vascular Parkinsonism: A Prospective, Randomized, Controlled Trial Protocol.Neuropsychiatric disease and treatment · 2026Article
- Comorbidity of white matter lesions in parkinson's disease: a study on risk factors and phenotypic differences.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- The role ofFrontiers in neuroscience · 2025Review
- Progress of radiomics research on white matter hyperintensity lesions.Frontiers in neurology · 2025Review
- Diagnostic Value of Carotid Intima-Media Thickness Combined with Periventricular White Matter Hyperintensities for Mild Cognitive Impairment in Parkinson's Disease.Neuropsychiatric disease and treatment · 2025Article
- The causal effects of gut microbiota on quantitative susceptibility mapping (QSM) and T2* imaging-derived phenotypes: insights from a Mendelian randomization study.Quantitative imaging in medicine and surgery · 2024Article
- Structural Disconnections Caused by White Matter Hyperintensities in Post-Stroke Spatial Neglect.Human brain mapping · 2024Article
- Association analyses of nutritional markers with Parkinson's disease and Alzheimer's disease.Heliyon · 2024Article
- Association analyses of apolipoprotein E genotypes and cognitive performance in patients with Parkinson's disease.European journal of medical research · 2024Article
- Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks.International journal of molecular sciences · 2023Review
- White matter changes in Parkinson's disease.NPJ Parkinson's disease · 2023Review
- Cognitive Deficits in Parkinson's Disease Are Associated with Neuronal Dysfunction and Not White Matter Lesions.Movement disorders clinical practice · 2023Article
- Age and sex differentially shape brain networks in Parkinson's disease.CNS neuroscience & therapeutics · 2023Article
- The impact of cerebral small vessel disease burden and its imaging markers on gait, postural control, and cognition in Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- QEEG Signatures are Associated with Nonmotor Dysfunctions in Parkinson's Disease and Atypical Parkinsonism: An Integrative Analysis.Aging and disease · 2023Article
- Application of Periventricular White Matter Hyperintensities Combined with Homocysteine into Predicting Mild Cognitive Impairment in Parkinson's Disease.International journal of general medicine · 2023Article
- Morphological basis of Parkinson disease-associated cognitive impairment: an update.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Cognitive profile in idiopathic autonomic failure: relation with white matter hyperintensities and neurofilament levels.Annals of clinical and translational neurology · 2022Article
- Retinal Nerve Fiber Layer Thickness and Associations With Cognitive Impairment in Parkinson's Disease.Frontiers in aging neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
The aim of this meta-analysis was to review systematically and to identify the relationship between the severity and location of white matter hyperintensities (WMHs) and the degree of cognitive decline in patients with Parkinson's disease (PD). We searched the PubMed, EMBASE, Web of Science, Ovid, and Cochrane Library databases for clinical trials of the severity and location of WMHs on the degree of cognitive impairment in PD through October 2020. We conducted the survey to compare the association of WMH burden in patients with PD with mild cognitive impairment (PD-MCI) versus those with normal cognition (PD-NC) and in patients with PD with dementia (PDD) versus those with PD without dementia (PD-ND). Nine studies with PD-MCI versus PD-NC and 10 studies with PDD versus PD-ND comparisons were included. The WMH burden in PD-MCI patients was significantly different compared to that in PD-NC patients (standard mean difference, SMD = 0.39, 95% CI: 0.12 to 0.66, p = 0.005), while there was no correlation shown in the age-matched subgroup of the comparison. In addition, PDD patients had a significantly higher burden of WMHs (SMD = 0.8, 95% CI: 0.44 to 1.71, p < 0.0001), especially deep white matter hyperintensities (SMD = 0.54, 95% CI: 0.36 to 0.73, p < 0.00001) and periventricular hyperintensities (SMD = 0.70, 95% CI: 0.36 to 1.04, p < 0.0001), than PD-NC patients, regardless of the adjustment of age. WMHs might be imaging markers for cognitive impairment in PDD but not in PD-MCI, regardless of age, vascular risk factors, or race. Further prospective studies are needed to validate the conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.